ERLOTINIB KRKA 25mg film-coated tablets medication leaflet

L01EB02 erlotinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Erlotinib is a medication used in the treatment of certain types of lung cancer and advanced pancreatic cancer. It works by blocking a protein involved in the growth and multiplication of cancer cells, thus helping to slow disease progression.

Erlotinib is administered orally as tablets, once daily, according to the oncologist's instructions. The dose may be adjusted depending on the patient's response to treatment and any side effects.

Side effects may include skin rashes, diarrhea, nausea, fatigue, or, rarely, liver dysfunction and severe allergic reactions. Medical monitoring is necessary throughout the treatment.

Erlotinib is an effective option for patients with advanced lung or pancreatic cancer, offering the chance to prolong survival and improve quality of life.

General data about ERLOTINIB KRKA 25mg

Substance: erlotinib

Date of last drug list: 01-03-2021

Commercial code: W67333001

Concentration: 25mg

Pharmaceutical form: film-coated tablets

Quantity: 30

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: KRKA, D.D., NOVO MESTO - SLOVENIA

Holder: KRKA, D.D., NOVO MESTO - SLOVENIA

Number: 13100/2020/01

Shelf life: 2 years

Concentrations available for erlotinib

100mg, 150mg, 25mg, 50mg